Compare RDHL & EOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDHL | EOCN |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.6M |
| IPO Year | 2012 | 2013 |
| Metric | RDHL | EOCN |
|---|---|---|
| Price | $0.39 | $3.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 821.0K | 6.4K |
| Earning Date | 09-30-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17,592.31 | N/A |
| Revenue Next Year | $25.89 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $2.33 |
| 52 Week High | $1.60 | $3.80 |
| Indicator | RDHL | EOCN |
|---|---|---|
| Relative Strength Index (RSI) | 33.24 | 46.11 |
| Support Level | N/A | $2.33 |
| Resistance Level | $0.71 | N/A |
| Average True Range (ATR) | 0.04 | 0.30 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 3.20 | 67.24 |
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.